Clinical trial
Phase II Trial of Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer
NCT00193388 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Trial of Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer
- Lead sponsor
- SCRI Development Innovations, LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2002
- Completion date
- February 28, 2007
- Enrollment
- 100
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
lung cancer